Beam Therapeutics Inc.
BEAM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,041 | $2,100 | $2,738 | $5,118 |
| - Cash | $282 | $436 | $233 | $966 |
| + Debt | $161 | $173 | $179 | $142 |
| Enterprise Value | $1,921 | $1,837 | $2,685 | $4,295 |
| Revenue | $64 | $378 | $61 | $52 |
| % Growth | -83.2% | 520% | 17.5% | – |
| Gross Profit | -$304 | $378 | -$251 | -$180 |
| % Margin | -478.7% | 100% | -411.5% | -347.8% |
| EBITDA | -$394 | -$147 | -$324 | -$230 |
| % Margin | -619.7% | -38.9% | -532.4% | -443.8% |
| Net Income | -$377 | -$133 | -$289 | -$371 |
| % Margin | -593.1% | -35.1% | -474.5% | -714.9% |
| EPS Diluted | -4.58 | -1.72 | -4.13 | -5.77 |
| % Growth | -166.3% | 58.4% | 28.4% | – |
| Operating Cash Flow | -$347 | -$149 | $23 | -$66 |
| Capital Expenditures | -$9 | -$34 | -$49 | -$47 |
| Free Cash Flow | -$356 | -$183 | -$26 | -$113 |